Loading…
Nurix Therapeutics, Inc. is projected to rise to $34.36 by 2027, a +39% move from its current price of $24.69. NRIX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $23.93 | $24.71 | $25.52 | +0.10% |
| Jul 13 | $23.64 | $24.74 | $25.89 | +0.20% |
| Jul 14 | $23.42 | $24.76 | $26.19 | +0.30% |
| Jul 15 | $23.24 | $24.79 | $26.44 | +0.40% |
| Jul 16 | $23.08 | $24.81 | $26.67 | +0.49% |
| Jul 17 | $22.95 | $24.84 | $26.88 | +0.59% |
| Jul 18 | $22.83 | $24.86 | $27.08 | +0.69% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.83 | $24.86 | $27.08 | +0.69% |
| Week 2 | $22.19 | $25.03 | $28.25 | +1.39% |
| Week 3 | $21.74 | $25.21 | $29.22 | +2.09% |
| Week 4 | $21.40 | $25.38 | $30.11 | +2.80% |
| Week 5 | $21.12 | $25.56 | $30.93 | +3.52% |
| Week 6 | $20.88 | $25.74 | $31.72 | +4.23% |
| Week 7 | $20.67 | $25.91 | $32.48 | +4.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
The company develops NX-5948, an orally bioavailable BTK degrader, in Phase 2 clinical trials for relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, in Phase 1a/1b clinical trials for relapsed or refractory B-cell malignancies; NX-1607, an orally bioavailable CBL-B inhibitor, in Phase 1a/1b to treat immuno-oncology indications; and NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
Nurix has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates.
The company was incorporated in 2009 and is headquartered in Brisbane, California, and it was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018.
Nurix Therapeutics, Inc. trades under the symbol NRIX and is currently priced at $24.26 per share with a market capitalization of $2.51B. It holds a rank of 1884 in market capitalization terms.
Technically, the stock shows a bullish tone with an RSI of 80, and it is trading above its moving averages: the SMA50 is $17.23 and the SMA200 is $15.50. Near-term support sits at $14.64 while resistance is at $24.26. The 30-day price range stretches from $19.18 to $30.69, indicating room for movement within a defined band.
A major floor 56.5% below — a decisive break under it would weaken the trend.
The nearest floor, 40.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 24.9% above — clearing it would confirm fresh momentum.
Key NRIX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NRIX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $24.10 | Buy | $23.84 | Buy |
| MA 10 | $23.94 | Buy | $23.26 | Buy |
| MA 20 | $21.07 | Buy | $21.67 | Buy |
| MA 50 | $18.26 | Buy | $19.26 | Buy |
| MA 100 | $17.03 | Buy | $17.84 | Buy |
| MA 200 | $16.04 | Buy | $16.54 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.26 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 44.11 | Neutral |
| Williams %R (14) | -26.99 | Info |
| MACD (12,26,9) | 0.17 | Buy |
| ROC (12) | 22.27 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 73.01 | Neutral |
| TRIX (15) | 1.45 | Buy |
| Awesome (5,34) | 4.91 | Buy |
| Ultimate (7,14,28) | 48.80 | Neutral |
| Momentum (10) | 0.60 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 24.21 | Buy |
| ADX (14) | 42.12 | Buy |
| ATR (14) | 0.56 | Info |
The 30-day technical picture is bullish.
RSI(14) is 80, suggesting strong momentum. The stock sits above the key moving averages: SMA50 at $17.23 and SMA200 at $15.50, signaling a positive trend in the near term.
Support is at $14.64 and resistance at $24.26, with the 30-day trading range between $19.18 and $30.69.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.43 | $24.69 | $37.82 | 0% | Neutral | |
| $26.89 | $34.36 | $46.72 | +39% | Bullish | |
| $28.11 | $37.15 | $52.70 | +50% | Bullish | |
| $31.17 | $42.35 | $62.12 | +72% | Bullish | |
| $32.37 | $45.10 | $68.00 | +83% | Bullish | |
| $38.91 | $55.46 | $85.67 | +125% | Bullish | |
| $48.40 | $70.47 | $111.23 | +185% | Bullish | |
| $52.63 | $78.17 | $125.82 | +217% | Bullish | |
| $57.43 | $86.95 | $142.48 | +252% | Bullish | |
| $58.58 | $90.33 | $150.51 | +266% | Bullish | |
| $89.87 | $150.72 | $269.14 | +510% | Bullish | |
| $177.76 | $345.79 | $682.44 | +13.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $14.43 | $24.69 | $29.54 | +0.00% |
| August 2026 | $21.65 | $25.68 | $31.38 | +4.02% |
| September 2026 | $22.58 | $27.02 | $33.44 | +5.19% |
| October 2026 | $22.66 | $27.30 | $34.16 | +1.05% |
| November 2026 | $23.02 | $27.91 | $35.24 | +2.23% |
| December 2026 | $24.37 | $29.70 | $37.82 | +6.43% |
Click any year to see its month-by-month NRIX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NRIX could reach as high as $37.82, with a base case around $24.69 and support toward $14.43 — roughly 0% from $24.69. Price action looks broadly range-bound.
Expect NRIX to range from $26.89 to $46.72 through 2027. The $34.36 average target implies a +39% move from current prices. That is up +39% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The NRIX price prediction for 2028 points to an average of $37.15 (low $28.11, high $52.70) — a potential gain of +50% on today's $24.69. Momentum favours further upside here.
In 2029, NRIX is projected to trade between $31.17 and $62.12, averaging $42.35 — a potential gain of +72% from today's $24.69. That is up +14% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Nurix Therapeutics, Inc.'s 2030 outlook centres on $45.10, within a $32.37 to $68.00 range. That is up +6% on the projected 2029 average. That marks a +83% change versus current levels. Momentum favours further upside here.
By 2031, NRIX could reach as high as $85.67, with a base case around $55.46 and support toward $38.91 — roughly +125% from $24.69. Buyers look set to stay in control over this stretch.
Expect NRIX to range from $48.40 to $111.23 through 2032. The $70.47 average target implies a +185% move from current prices. That is up +27% on the projected 2031 average. Momentum favours further upside here.
The NRIX price prediction for 2033 points to an average of $78.17 (low $52.63, high $125.82) — a potential gain of +217% on today's $24.69. Buyers look set to stay in control over this stretch.
In 2034, NRIX is projected to trade between $57.43 and $142.48, averaging $86.95 — a potential gain of +252% from today's $24.69. That is up +11% on the projected 2033 average. Momentum favours further upside here.
Nurix Therapeutics, Inc.'s 2035 outlook centres on $90.33, within a $58.58 to $150.51 range. That is up +4% on the projected 2034 average. That marks a +266% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, NRIX could reach as high as $269.14, with a base case around $150.72 and support toward $89.87 — roughly +510% from $24.69. Momentum favours further upside here.
Expect NRIX to range from $177.76 to $682.44 through 2050. The $345.79 average target implies a +13.0x move from current prices. That is up +129% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NRIX today (≈ 40.502228 NRIX) could be worth
$14,005.18
+$13,005.18 (+1301%) by 2050 · US Dollar
Based on the average projected NRIX price of $345.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NRIXwould be worth at today's price.
$1,000 invested in NRIX on Jul 10, 2025 (≈ 78.926598 NRIX) would be worth
$1,948.7
+$948.7 (+94.9%) today · 1.95× · US Dollar
Based on a NRIX entry price of $12.67 vs. today's $24.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.97 | $1,030.04 | +3.0% |
| 1 month ago | $15.3 | $1,613.73 | +61.4% |
| 3 months ago | $16.03 | $1,540.24 | +54.0% |
| 6 months ago | $18.38 | $1,343.31 | +34.3% |
| 1 year ago | $12.67 | $1,948.7 | +94.9% |
| All time (5.0y) ago | $23.92 | $1,032.19 | +3.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NRIX forecast.
Our base-case forecast reaches $49.00 around 2031.
Implied market cap at $49.00: $5.09B
The multi-year forecast for NRIX shows a path of substantial upside potential. The average price rises from $24.26 in 2026 to $392.19 in 2050, while the implied max price climbs to $807.94 by 2050. In 2030, the average price is projected at $45.29 with a corresponding ROI of 86.7%.
By 2040, the average is forecast at $164.15 with a ROI of 576.6%, and by 2050 the average is $392.19 with a ROI of 1516.6%.
The outlook is described as BULLISH in most years, with 2026 marked as NEUTRAL and a 0% ROI, then turning bullish in 2027 and continuing higher through 2050. The forecast also shows significant growth in the later years, underscoring the potential for meaningful upside but also the inherent uncertainty and volatility implied by long-horizon projections.
Tap a question to reveal the answer.
In 2030, the forecasted average price is $45.29, with a min of $31.76 and a max of $70.02, and a potential ROI of 86.7%. The sentiment is BULLISH.
Forecasts show a bullish path beyond 2026, with the average price rising from $24.26 in 2026 to $392.19 by 2050 and ROIs increasing to 86.7% in 2030 and 1516.6% by 2050. Sentiment is NEUTRAL in 2026 and BULLISH from 2027 onward.
Yes. The forecast shows a max price of $156.97 in 2034 and $165.37 in 2035, and a max of $304.08 in 2040, indicating the price could exceed $100 within the forecast horizon.
The 2040 forecast shows an average price of $164.15, a min of $93.08, a max of $304.08, and a ROI of 576.6 with a BULLISH sentiment.
For 2050, the forecast is an average of $392.19, a min of $186.77, a max of $807.94, and a ROI of 1516.6, with a BULLISH sentiment.
Nurix Therapeutics, Inc. Community Discussion
0Share your Nurix Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.